Cohere Health: Company Profile for the Clinical AI Prior Authorization and Payment Integrity Platform

Company Overview: Founding, Mission, and Leadership

Cohere Health was founded in 2019 in Boston, Massachusetts, by Siva Namasivayam, who serves as CEO. Namasivayam previously served as CEO of SCIO Health Analytics, a healthcare analytics company acquired for approximately $240 million. That background in payer-side analytics shapes Cohere Health's foundational premise: that prior authorization is not primarily an administrative gatekeeping function but a clinical intelligence problem — one where better data, better models, and better workflow integration can simultaneously reduce administrative burden and improve care appropriateness.

The company's stated mission is to help people receive the right care at the right time, in the right place, and with the right value. In operational terms, this translates to building AI systems that help health plans make faster, more clinically defensible utilization management decisions — while reducing the friction that prior authorization creates for providers and patients.

Cohere Health positions itself as a clinical intelligence company rather than a denial-management tool. Its public communications and product architecture consistently emphasize that no authorization request is denied exclusively by AI — a design principle that distinguishes it from some automated review tools that have drawn regulatory and professional scrutiny.

Funding History and Investor Composition

Cohere Health has raised approximately $200 million in total disclosed funding across four rounds from 2020 through May 2025. The company remains private as of Q2 2026; revenue figures and valuation are not independently verifiable.

The Series C, announced in May 2025, was led by Temasek — the Singapore-based sovereign wealth fund — and brought total funding to $200 million. Flare Capital Partners' Michael Greeley noted at the time of the raise that Cohere had achieved strong provider satisfaction and had "dominated this category." That characterization reflects investor perspective, not an independent market assessment.

The February 2024 growth equity round, led by Deerfield Management, was positioned as a bridge to accelerate product expansion ahead of the Series C. Deerfield's continued participation in the Series C suggests sustained conviction from a healthcare-focused investment firm with deep payer-side relationships.

Platform Architecture: Cohere Unify and the AI Model Layer

Cohere Unify is the company's core AI platform — the technical foundation that underpins all of its product offerings. According to company disclosures, the platform is built on more than 350 clinician-trained, domain-specific fine-tuned models. Cohere Health reports that these models consistently outperform general-purpose large language models on clinical utilization management tasks, though no independent benchmarking has been published to substantiate this claim as of Q2 2026.

The platform is structured around an episode-of-care authorization design, meaning it is built to manage authorization across the full clinical episode — not just individual service-level requests. This design is intended to reduce redundant PA submissions for related services within a single care episode, a structural improvement over legacy transaction-by-transaction authorization workflows.

An agentic AI layer sits atop the model stack, enabling the platform to orchestrate multi-step clinical review tasks with reduced manual intervention. Cohere Health describes this as its enterprise agentic AI strategy — positioning Cohere Unify as an AI layer that can operate on top of legacy health plan systems rather than requiring full system replacement.

Responsible AI Principles and Human-in-the-Loop Design

Cohere Health's stated responsible AI principles center on one operational commitment: no authorization request is denied exclusively by AI. The company reports that approximately 85% of requests receive real-time AI-driven decisions — the vast majority of which are approvals. The remaining 15% are routed to a hybrid review queue staffed by nurses and physicians, who use an AI co-pilot to assist their review. CEO Namasivayam has noted that this co-pilot reduces physician review time from 40–50 minutes to approximately 10 minutes per case.

Infrastructure, Security, and Compliance Certifications

• Hosted on Amazon Web Services (AWS) infrastructure.
• Data encryption: AES-256 at rest; TLS 1.2+ in transit.
• HITRUST CSF certified.
• NCQA certified (relevant for health plan accreditation contexts).
• URAC certified.
• HIPAA compliant.
• CMS-0057-F compliant via FHIR API stack (CRD, DTR, PAS).

Product Suite: From Prior Authorization to Payment Integrity

Between 2024 and 2026, Cohere Health expanded from a focused prior authorization platform into a multi-product clinical intelligence suite covering outpatient and inpatient authorization, policy management, provider-facing submission tooling, and payment integrity. The September 2025 acquisition of ZignaAI — a payment integrity AI company founded in 2020 — marked the most significant expansion of scope, extending the platform from pre-care authorization into post-service claims validation.

Cohere Connect and EHR Integration Context

Cohere Connect is the product most directly implicated by CMS-0057-F compliance requirements. It provides FHIR-based Coverage Requirements Discovery (CRD), Documentation Templates and Rules (DTR), and Prior Authorization Support (PAS) APIs — the three interoperability standards mandated under the CMS Interoperability and Prior Authorization Final Rule. The company reports that Cohere Connect has supported more than 15 million PA submissions and integrates with Epic, Rhyme, Availity, and NaviNet. For health IT teams evaluating interoperability readiness, the TEFCA and FHIR interoperability infrastructure for clinical AI provides additional context on the FHIR data exchange standards underpinning these API integrations.

Payment Integrity Suite and the ZignaAI Acquisition

On September 9, 2025, Cohere Health announced the acquisition of ZignaAI, a company founded in 2020 specializing in AI-driven payment integrity. The acquisition launched the Cohere Payment Integrity Suite, anchored by Cohere Validate. Financial terms of the acquisition were not publicly disclosed.

Cohere Validate applies AI to inpatient, outpatient, and professional claims audit programs — identifying coding errors, clinical documentation gaps, and potential overpayments after care has been delivered. The company reports 8–9x ROI and a 58% sepsis audit findings rate for Cohere Validate, though these figures are drawn from company disclosures and have not been independently verified. Cohere Match, launched alongside Validate, reconciles claims against prior authorizations to identify cases where services were delivered without corresponding authorization — a payment integrity function distinct from clinical review.

Regulatory and Compliance Posture

The most significant regulatory requirement currently shaping Cohere Health's product roadmap is CMS-0057-F — the CMS Interoperability and Prior Authorization Final Rule, which mandates that impacted health plans implement FHIR-based electronic prior authorization APIs by January 2027. Cohere Connect directly addresses these requirements through its CRD, DTR, and PAS API stack. For a comprehensive analysis of CMS-0057-F and the broader federal prior authorization regulatory framework, see CMS Prior Authorization and AI: How Three Federal Rules Are Reshaping Utilization Management. This profile does not reproduce the full rule summary but focuses on how Cohere Connect addresses the specific compliance requirements.

Beyond CMS-0057-F, Cohere Health holds HITRUST CSF, NCQA, and URAC certifications — the three most commonly required compliance credentials for health plan technology vendors. HITRUST certification is particularly relevant for enterprise health plan procurement, as it serves as a consolidated security and privacy assurance framework. NCQA and URAC certifications signal alignment with health plan accreditation standards, which matters for payers subject to those accreditation programs.

Deployment Outcomes and Case Studies: Evidence Quality Assessment

Geisinger Health Plan Deployment

Cohere Health's most frequently cited deployment case is Geisinger Health Plan, with a go-live date reported as July 2022. According to company-disclosed case study data, the Geisinger deployment produced the following outcomes:

• 15% incremental medical expense reduction (company-reported case study)
• 63% reduction in prior authorization denials (company-reported case study)
• 70% faster care access for members (company-reported case study)
• 95% digital PA submission rate (company-reported case study)
• 18% reduction in surgical complications (company-reported case study)

These figures are drawn from Cohere Health press releases and case study materials. They have not been published in a peer-reviewed journal, subjected to independent statistical audit, or validated by an external research team. The 18% reduction in surgical complications figure in particular warrants scrutiny: attributing a surgical complication rate change to a prior authorization platform involves multiple confounding variables that a case study methodology cannot adequately control for.

Humana MSK Partnership

Cohere Health's partnership with Humana for musculoskeletal (MSK) prior authorization began in October 2020 and is reported to cover approximately 2 million members across more than 3,500 physician practices. The partnership uses an episode-of-care authorization model for MSK services — authorizing a bundle of related services at the episode level rather than requiring individual authorizations for each component.

KLAS Research awarded a 2022 Points of Light recognition to the Humana/Cohere Health/provider collaboration — an acknowledgment of notable innovation in healthcare IT, not a clinical outcomes certification. Cohere Health has received this recognition from KLAS three times in total.

Provider Satisfaction Survey Data

Cohere Health reports 94% provider satisfaction across more than 600,000 providers in its network. This figure derives from a company-reported internal survey — not an independently administered provider satisfaction study. The survey methodology, response rate, question framing, and sampling approach are not publicly documented, which limits the interpretability of this figure for procurement purposes.

Known Limitations and Critical Context

The Evidence Quality Gap

The most significant limitation for procurement decision-makers evaluating Cohere Health is the absence of large-scale independent peer-reviewed evidence for its platform's clinical and financial outcomes. Every major performance metric the company has published — the 15% medical expense reduction at Geisinger, the 63% denial reduction, the 85% real-time approval rate, the 94% provider satisfaction figure — originates from company press releases, company-commissioned case studies, or internal surveys.

A 2025 quality improvement study published in JAMA Network Open (PMC12723545) examined AI-integrated prior authorization at Northwell Health and found meaningful reductions in denial rates and authorization time. However, that study evaluated InsightRT, a platform developed by Siris Medical (a division of TurningPoint Healthcare Solutions) — a different product and company from Cohere Health. It cannot be cited as evidence for Cohere Unify's performance. It is useful as contextual evidence that clinically integrated PA tools can produce measurable outcomes, but the platforms are not interchangeable.

Physician Concerns About AI in Prior Authorization

Cohere Health's own 2025 National Provider Survey — a company-commissioned survey of 200 clinicians and office staff — reported high confidence in AI-driven PA. The American Medical Association's independently conducted survey of 1,000 physicians offers a materially different picture of the broader landscape.

• 3 in 5 physicians surveyed by the AMA were concerned that health plan AI in prior authorization may be increasing denials.
• 1 in 3 AMA survey respondents agreed that PA requirements lack clinical or research-based evidence.
• Some AI-driven PA systems have been reported to produce denial rates 16 times higher than normal human review rates.
• 29% of physicians in the AMA survey reported that PA delays or denials had led to a serious adverse event for a patient.

AMA President Bruce A. Scott, MD stated in connection with the AMA survey that insurers use automated decision-making systems to create systematic batch denials with little or no human review. These concerns are directed at health plan AI in prior authorization broadly — they are not specific accusations against Cohere Health's platform. However, they establish the regulatory and professional environment in which Cohere operates and represent the counterpoint that procurement teams should weigh alongside company-reported satisfaction data.

AI Bias, Data Provenance, and Model Drift Risks

Cohere Health's models are trained on historical utilization management data. Any model trained on historical authorization patterns risks encoding existing disparities — including demographic, geographic, and socioeconomic patterns in care access and denial rates — into its decision logic. The company has not published a demographic bias audit of its models as of Q2 2026.

Model drift — the degradation of model performance as real-world data distributions shift away from training conditions — is a structural risk for any AI system deployed in dynamic clinical environments. Health plans deploying Cohere Health's platform should establish ongoing monitoring programs to detect performance drift over time. For a practical framework on this, see building an institutional monitoring program for clinical AI model drift.

Data provenance is a related concern: the clinical guidelines, payer policies, and utilization patterns used to train Cohere's models are not publicly documented. Buyers cannot independently assess whether the training data reflects current clinical evidence standards or historical utilization norms that may not align with contemporary best practices.

Market Recognition and Competitive Position

Cohere Health has accumulated significant industry recognition between 2022 and 2026. The following reflects documented third-party acknowledgments, not clinical outcome endorsements.

• Gartner Hype Cycle for U.S. Healthcare Payers: featured for four consecutive years, 2022–2025.
• TIME World's Top HealthTech Companies 2025.
• Inc. 5000 fastest-growing private companies, 2025.
• Deloitte Technology Fast 500, ranked #218, 2025.
• HLTH 2025 Best in Class Award for AI in Health Operations.
• KLAS Points of Light recipient three times, including 2022 recognition for the Humana MSK collaboration.

Strategic Trajectory and 2026 Outlook

Cohere Health's 2025 activity signals a deliberate expansion from a focused outpatient prior authorization company into a broader clinical intelligence platform. The company closed ten new health plan deals in 2025, including one supporting CMS directly in its efforts to reduce waste and abuse in healthcare — a notable signal of federal-level engagement.

The product expansion across 2025 covers three distinct vectors: inpatient authorization (Review Assist), policy management infrastructure (Policy Studio), and post-service payment integrity (Validate, Match, and the ZignaAI acquisition). This trajectory moves Cohere Health's platform from a pre-care authorization tool toward a continuous clinical intelligence layer spanning the full utilization management and payment integrity lifecycle.

CEO Namasivayam has publicly identified care management as the next expansion frontier — a domain that would extend Cohere's reach from authorization and payment into ongoing clinical program management for high-cost member populations. No product announcements in care management had been made as of Q2 2026.

The enterprise agentic AI strategy positions Cohere Unify as an AI orchestration layer that health plans can deploy on top of existing legacy systems — reducing the integration barrier that has historically slowed adoption of new payer-side technology. This framing is consistent with the broader trend in enterprise healthcare AI toward platform approaches rather than point solutions.

For health system administrators and CIOs evaluating the enterprise clinical AI landscape, Cohere Health occupies a distinct buyer persona from ambient documentation platforms such as Abridge — which serves provider organizations with clinical documentation AI — or genomics AI platforms such as Tempus AI, which serves precision oncology programs. Cohere Health's primary buyers are health plan medical management and operations teams, not clinical departments or provider organizations — though its provider-facing tools (Align, Connect) are designed to reduce friction on the provider side of the authorization transaction.